Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.79 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.60 |
| ▸ | GRM7 | Q14831 | 3/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827706 | 0.89 | MTNR1A (1.00) | MTNR1AMTNR1BMAPTCYP1A2ALOX15 | |
| SCHEMBL4112887 | 0.89 | MTNR1A (1.00) | MTNR1AMTNR1BMAPTCYP1A2ALOX15 | |
| SCHEMBL2597383 | 0.89 | MTNR1A (1.00) | MTNR1AMTNR1BMAPTCYP1A2ALOX15 | |
| SCHEMBL9731832 | 0.85 | MTNR1A (0.91) | MTNR1AMTNR1BMAPTCYP1A2ALOX15 | |
| SCHEMBL18263517 | 0.84 | MTNR1A (0.59) | MTNR1AMTNR1BMAPTCYP1A2ALOX15 | |
| SCHEMBL6559473 | 0.82 | CA1 (0.68) | MTNR1AMTNR1BMAPTCYP1A2ALOX15 | |
| SCHEMBL4865313 | 0.81 | MTNR1A (0.79) | MTNR1AMTNR1BMAPTKMT2AGRM7 | |
| SCHEMBL1628829 | 0.81 | MAPT (0.63) | MTNR1AMTNR1BMAPTCYP1A2ALOX15 | |
| SCHEMBL27731471 | 0.81 | MAPT (0.63) | MTNR1AMTNR1BMAPTCYP1A2ALOX15 | |
| SCHEMBL8569805 | 0.81 | EPHX2 (0.64) | MTNR1AMTNR1BMAPTCYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20120316173-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120252807-A1 | ARBOVIRUS INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-04 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| WO-2011143772-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| EP-1091946-A1 | NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE | WIKSTRÖM, Hakan Vilhelm (NL) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001680-A1 | NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE | WIKSTROEM HAKAN VILHELM (NL) | 2000-01-13 | — | — | WO | disclosed |
| EP-0579059-B1 | Pyridazinone derivatives and processes for preparing the same | TANABE SEIYAKU CO (JP) | 1999-05-12 | — | — | EP | disclosed |
| US-5605901-A | THERAPY FOR GRAM-NEGATIVE BACTERIA, NEPHRITIS | TANABE SEIYAKU CO., LTD. (JP) | 1997-02-25 | — | — | US | disclosed |
| US-5543409-A | Indane derivatives for treating endotoxin shock and/or nephritis | TANABE SEIYAKU CO., LTD. (JP) | 1996-08-06 | — | — | US | disclosed |
| EP-0661274-A1 | Indane derivatives, processes for preparing the same and synthetic intermediate of the same | TANABE SEIYAKU CO., LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
| EP-0579059-A1 | Pyridazinone derivatives and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1994-01-19 | — | — | EP | disclosed |
| US-5272157-A | Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application | SYNTHELABO (FR) | 1993-12-21 | — | — | US | disclosed |
| US-5179108-A | Antiserotonin agents or cardiovascular disorders | SYNTHELABO (FR) | 1993-01-12 | — | — | US | disclosed |
| EP-0447292-A1 | 4-Aminomethyl-piperidine derivatives, their preparation and therapeutic application | SYNTHELABO (FR) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | MTNR1A 41/4885MTNR1B 46/4885MAPT 3490/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MTNR1A 823/4885MTNR1B 815/4885MAPT 458/4885 |
| US-20120316173-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | CNR2, CNR1, OPRL1 | MTNR1A 79/4885MTNR1B 39/4885MAPT 3628/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | MTNR1A 41/4885MTNR1B 46/4885MAPT 3490/4885 |
| US-20120252807-A1 | ARBOVIRUS INHIBITORS AND USES THEREOF | ACE, ACE2, MME | MTNR1A 2193/4885MTNR1B 1545/4885MAPT 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.